BSE
Your Result on : Company News Details
Cipla Ltd Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
500087
ISIN Demat
INE059A01026
Book Value (Rs)
432.1356994
NSE Symbol
CIPLA
Divident Yield %
0.92
Market Cap
(Rs In Cr.)
114,720
P/E (TTM)
40.17
EPS (TTM)
35.35
Face Value
(Rs)
2
Back
Cipla inks exclusive partnership with Qilu Pharma for commercializing Pembrolizumab in US
04-Sep-26   Hrs IST

Cipla said that its wholly owned subsidiary Invagen Pharmaceuticals has entered into a strategic partnership with Qilu Pharmaceutical Co. for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), for United States.

Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both finished dosage forms (FDFs) and active pharmaceutical ingredients (APIs).

As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory.

Achin Gupta, managing director & global chief executive officer, Cipla, said, “This partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio.

By combining Qilu’s development strengths with Cipla’s commercial presence and patient-centric legacy, we aim to expand access to high-quality biologics for patients across our focus markets.'

Cipla is a global pharmaceutical company with operations across India, South Africa, North America and other regulated and emerging markets. The company focuses on complex generics and therapies including respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla operates 46 manufacturing facilities globally, producing more than 1,500 products across over 80 markets.

The company’s consolidated net profit declined 39.19% to Rs 789.05 crore in Q1 FY27, compared with Rs 1,297.62 crore posted in Q1 FY26. Revenue from operations increased 3.51% YoY to Rs 7,077.02 crore in the quarter ended 30th June 2026.

The scrip shed 0.58% to currently trade at Rs 1380.90 on the BSE.

Risk Factor   |   Terms & Conditions   |   Privacy Policy   |   Disclaimer   |  Sitemap 
Important Links:   SEBI   |   NSE   |   BSE   |   MCX   |   NCDEX   |   NSDL   |   CDSL  |   FMC
BSE Delayed market data sourced at 5 minutes – www.bseindia.com
SMS FINANCIAL SERVICES P. LTD -NSE SEBI No. AP1413004363 | BSE SEBI No. AP01091801121968
Ganesh S Shanbhag – AMFI Registered Mutual Fund Distributor. Registration Number – ARN-0988 – Valid Till 01/JUL/ 2027, Date of initial registration: 02/DEC/2004
2017-18 © SMS Financial Services. All rights reserved. Designed, Developed , Maintained and Content Powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)